Can medicines development improve outcomes in asthma and chronic obstructive pulmonary disease management by driving effectiveness?


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
02 Aug 2019
Historique:
received: 14 01 2019
accepted: 08 07 2019
entrez: 4 8 2019
pubmed: 4 8 2019
medline: 29 1 2020
Statut: epublish

Résumé

Despite the availability of treatment guidelines and inhaled medications for asthma and chronic obstructive pulmonary disease (COPD), much remains to be done to lessen the burden of these respiratory diseases for patients. The challenge of selecting effective and efficacious drugs for patients is a key focus area for healthcare professionals. Here we discuss the concept of "drivers of effectiveness"- features of a medicine which may increase or decrease its effectiveness in the presence of real-world factors - and highlight the importance of considering these drivers in the early stages of drug development, and exploring their impact in carefully designed pragmatic trials. Using the Salford Lung Studies (SLS) in asthma and COPD as an illustrative example, we discuss various features of the inhaled corticosteroid/long-acting β

Identifiants

pubmed: 31375102
doi: 10.1186/s12931-019-1127-6
pii: 10.1186/s12931-019-1127-6
pmc: PMC6679431
doi:

Substances chimiques

Anti-Asthmatic Agents 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

173

Subventions

Organisme : GlaxoSmithKline plc
ID : N/A

Références

BMC Pulm Med. 2010 Jan 05;10:1
pubmed: 20051135
Lancet. 2017 Nov 18;390(10109):2247-2255
pubmed: 28903864
Eur Heart J. 1996 Mar;17 Suppl A:8-15
pubmed: 8737195
Respir Res. 2018 Jul 13;19(1):133
pubmed: 30001712
Respir Med. 2017 Aug;129:117-123
pubmed: 28732818
NPJ Prim Care Respir Med. 2018 Jan 17;28(1):2
pubmed: 29343739
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Int Arch Allergy Immunol. 2005 Nov;138(3):225-34
pubmed: 16210861
Eur Respir J. 2014 Mar;43(3):763-72
pubmed: 24114969
Value Health. 2014 Nov;17(7):A586
pubmed: 27201991
Respir Med. 2019 Apr;150:1-7
pubmed: 30961933
J Allergy Clin Immunol. 2002 Jul;110(1):58-64
pubmed: 12110821
Respir Med. 2003 Jul;97(7):835-43
pubmed: 12854635
Curr Med Res Opin. 2005;21 Suppl 4:S5-9
pubmed: 16138939
Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):411-22
pubmed: 18205251
Arch Bronconeumol. 2010 Oct;46 Suppl 6:8-13
pubmed: 21316543
Eur Respir J. 2005 Dec;26(6):1047-55
pubmed: 16319334
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1488-1496.e7
pubmed: 30639604
Respir Med. 2016 Oct;119:115-121
pubmed: 27692131
Respir Res. 2015 Sep 04;16:101
pubmed: 26337978
Respir Med. 2001 Aug;95 Suppl B:S7-11
pubmed: 11534896
Pulm Pharmacol Ther. 2015 Apr;31:68-78
pubmed: 25727846
J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97
pubmed: 26372467
Respir Med. 2011 Jun;105(6):930-8
pubmed: 21367593
Chest. 2013 Oct;144(4):1222-1229
pubmed: 23846316
Respir Med. 2008 Dec;102(12):1681-93
pubmed: 18815019
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):785-793
pubmed: 29339126
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44
pubmed: 15256389
BMC Pulm Med. 2015 Dec 10;15:160
pubmed: 26651333
N Engl J Med. 2016 Sep 29;375(13):1253-60
pubmed: 27593504
Br J Clin Pharmacol. 2015 Sep;80(3):372-80
pubmed: 25808113
BMC Pulm Med. 2007 May 22;7:8
pubmed: 17518999
Lancet. 2017 Sep 2;390(10098):935-945
pubmed: 28797514
Patient. 2013;6(3):213-24
pubmed: 23857628
J Asthma. 2018 Sep;55(9):984-993
pubmed: 28961020
CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00004
pubmed: 26225235
NPJ Prim Care Respir Med. 2016 Nov 24;26:16079
pubmed: 27883002
Thorax. 2002 Oct;57(10):889-96
pubmed: 12324677
Pulm Ther. 2018 Dec;4(2):135-147
pubmed: 32026395
NPJ Prim Care Respir Med. 2018 Nov 16;28(1):43
pubmed: 30446655
PLoS One. 2015 Jan 05;10(1):e0116207
pubmed: 25559848
Thorax. 2014 Dec;69(12):1152-4
pubmed: 24603195
Respir Med. 2013 Oct;107(10):1481-90
pubmed: 23643487

Auteurs

David A Leather (DA)

Global Respiratory Franchise, GlaxoSmithKline plc., Brentford, Middlesex, UK. david.a.leather@gsk.com.

Louisa Yates (L)

Global Respiratory Franchise, GlaxoSmithKline plc., Brentford, Middlesex, UK.

Henrik Svedsater (H)

Value Evidence & Outcomes, GlaxoSmithKline plc., Brentford, Middlesex, UK.

Loretta Jacques (L)

Clinical Sciences, GlaxoSmithKline plc., Uxbridge, Middlesex, UK.

Susan Collier (S)

UK Medical, GlaxoSmithKline plc., Uxbridge, Middlesex, UK.

Danielle Powell (D)

Global Respiratory Franchise, GlaxoSmithKline plc., Brentford, Middlesex, UK.

Rupert Jones (R)

Community and Primary Health Care, Faculty of Medicine and Dentistry, Plymouth University, Plymouth, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH